autologous anti-CSPG4 CAR-iC9-expressing T lymphocytes

{
  "id": "MLC-T-ONC-011420",
  "term": "autologous anti-CSPG4 CAR-iC9-expressing T lymphocytes",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for chondroitin sulfate proteoglycan 4 (CSPG4) and the suicide gene inducible caspase 9 (iCasp9 or iC9), with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CSPG4 CAR-iC9-expressing T lymphocytes specifically target and bind to CSPG4-expressing tumor cells, resulting in tumor cell lysis. CSPG4 is overexpressed on a variety of tumor cell types. The iCasp9 safety switch consists of a full-length caspase 9, including its caspase recruitment domain, linked to a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V). If the administered CAR T cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered. AP1903 binds to the FKBP12-F36V drug-binding domain, activates caspase 9 and results in apoptosis of the administered CAR T cells.",
  "synonyms": [
    "autologous anti-CSPG4 CAR-iC9-expressing T cells",
    "autologous anti-CSPG4 CAR-iCasp9-expressing T cells",
    "autologous iC9-CSPG4 CAR T cells",
    "iC9-CAR.CSPG4 T cells"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/autologous-anti-cspg4-car-ic9-expressing-t-lymphocytes/"
}